---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-015778"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T02:14:37.652380+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics Q1 net loss $2.7M, cash $27.7M; stenoparib shows durable benefit

## Summary
- Net loss narrowed to $2.7M in Q1 2025 from $3.8M in Q1 2024; R&D expenses $1.4M, G&A $1.6M.
- Cash and restricted cash $27.7M at March 31, 2025, up from $20.9M at December 31, 2024.
- Two ovarian cancer patients on stenoparib >19 months; new Phase 2 protocol for platinum-resistant disease begins H1 2025.
- VA-funded Phase 2 trial of stenoparib + temozolomide in SCLC to begin enrollment Q2-Q3 2025.
- Authorized $5M share repurchase program; ~2M shares bought; SEC settlement and class action lawsuit resolved.

## SEC filing metadata
- accession: 0001437749-25-015778
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925015778/0001437749-25-015778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925015778/allr20250509_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-015778
- JSON: https://secwatch.observer/filing/0001437749-25-015778.json
- Plain text: https://secwatch.observer/filing/0001437749-25-015778.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.